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Received 31 August 2007; accepted 5 September 2007Myocardial infarction (heart attack) results in severe damage
to the heart muscle. Post-infarction, heart function is
compromised as a result of cardiomyocyte death and an
acute inflammatory response that is a prelude to deposition
of permanent scar tissue. Long-term molecular, cellular and
physiological responses to the damaged muscle result in
disease progression to heart failure. The progression from
ischaemic injury to heart failure highlights the limited
regenerative reserve of cardiac tissue in man. This is
contrasted by an extraordinary ability of the zebrafish
heart to regenerate after resection of 20% of its ventricular
mass, via formation of a fibrous clot and cellular blastema, in
60 days (Poss et al., 2002). Nevertheless, multipotent
cardiac stem cells appear to exist in mammals and recent
genetic fate mapping experiments have revealed that a non-
myocyte population can repopulate the myocardium in
response to cardiac stress, including infarction and pressure
overload, but do not significantly contribute to the cardio-
myocyte population homeostatically during normal aging
(Hsieh et al., 2007). Furthermore, recent experiments
suggest that mammalian hearts might be coaxed into a
regenerative model, including formation of new cardiomyo-
cytes, by a cocktail of factors given at the time of infarction
(reviewed in Ballard and Edelberg, 2007).
In humans, stem cell-based therapies offer the potential
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doi:10.1016/j.scr.2007.09.001disease progression. Promising initial results of stem cell-
based therapy in animal disease models lead to the rapid
transfer of this approach from the laboratory to the clinic
(Srivastava and Ivey, 2006). However, such an enthusiastic
leap belies the recent emergence of the methodology and, in
particular, the rudimentary understanding of the biological
mechanisms underlying the improvements to heart function
observed. Indeed, early positive indications for the use of
bone-marrow stem cell fractions or mobilisation regimes to
repair myocardium have been controversial (Kovacic et al.,
2005; Srivastava and Ivey, 2006) and results from large,
double-blinded, controlled, cell therapy studies involving
clinical outcomes have only just started to emerge (Ballard
and Edelberg, 2007).
However, the ultimate cell type or therapy for cardiac
repair is at this point unknown, and direct delivery of
differentiated cardiomyocytes to the diseased heart (myo-
cardial replacement therapy; MRT)may have advantages over
endogenous or exogenous stem cell-mediated repair espe-
cially in the aged, in whom both systemic and local factors
that would normally support stem cell survival and deploy-
ment may have long waned (Ballard and Edelberg, 2007;
Rando, 2006). Recent reports using ES cell-derived cardio-
myocytes in both intra-species and xeno-transplantation
studies suggest that cardiomyocytes generated in this way
offer an unlimited supply of suitable cells for MRT and may
improve heart function post-myocardial infarction (Kehat
et al., 2004; Kolossov et al., 2006; Tomescot et al., 2007).
In this issue of Stem Cell Research, van Laake and colleges
present a detailed and instructive study using human ES cell
(HESC)-derived cardiomyocytes injected into healthy and
diseased mouse hearts (van Laake et al., 2007). Cells
5Time to mend a broken heartinjected consisted of dissociated tissue dissected from
cultures in which HESCs were differentiated in the presence
of an endodermal cell line with the capacity to augment
cardiogenesis, and as such represent a mixed pool with an
estimated cardiomyocyte (CM) content of 20–25%. The
injected CMs form a small, functioning, isolated syncytium
within the normal host ventricle. In the context of cell
therapy, it was promising that the engrafted immature CMs
gradually matured, shown by the formation of both desmo-
somes and gap junctions, and activation of the adult
myocardial markers MLC2v and Connexin-43. Furthermore,
the CMs were positively selected for survival. These data
complement those found when using mouse ES cell-derived
CMs, which also formed an isolated syncytium that matured
over time (Kolossov et al., 2006). Similarly, HESC-derived
CMs did not functionally integrate with the host myocardium
but instead were shown to remain in isolated grafts
separated from host CMs by extracellular matrix. Previous
studies have demonstrated integration of HESC-derived CMs
into host myocardium, but only in non-ischaemic conditions
(see Kehat et al., 2004; Laflamme et al., 2007). The reason
for this is unknown, but may reflect the different maturation
state or biophysical properties of host and graft tissue, for
example, in this case, the large discrepancy between mouse
and human heart rates may prevent incorporation of HESC-
derived CMs into the myocardium.
Next the authors investigated the potential of the HESC-
derived CMs in a mouse model of ischemic heart disease.
Introduction of CMs into damaged heart tissue resulted in
improved cardiac performance parameters at 4 weeks post-
infarction. However, at 12 weeks post-infarction no differ-
ence was observed between experimental and control mice.
This finding illustrates the importance of evaluating the long-
term contribution of CMs, or indeed any engrafted cells, that
appear to promote cardiac function in the shorter time
frame. The analysis presented by van Laake and colleagues
suggests that a non-cell autonomous mechanism initially
improves heart function, but as the graft becomes estab-
lished this signal is downregulated or lost, diminishing the
difference in contractile function between experimental and
control animals. Cautious interpretation of these data is
required. While it may be tempting to suggest that the
greatest level of functional support in these and other cell
therapy studies is provided by trophic rather that biomecha-
nical effects, perhaps via augmentation of vasculogenesis
and cardiomyocyte survival, the transient nature of the
response demands closer scrutiny. We can nonetheless
remain hopeful that MRT will offer much greater levels of
long-term biomechanical support to the diseased heart than
are evident in this study. Technical difficulties such as the
low survival rate of directly injected myocytes and their poor
level of integration with host myocardium have perhaps
affected the outcome in the current protocol. If proper
electrical integration of myocytes can be achieved, the
effect may be sustained. Future experiments using mamma-
lian models with more closely matched host and donor cells
will be necessary to carefully dissect the roles of injected
cells in providing trophic and biomechanical support. In the
longer term, the bland infarct model in an immunocompro-
mised host shows a very different post-infarction inflamma-
tory response than humans or mice whose coronary vessels
have been re-perfused, and this may shape the ultimateoutcome of cell therapy. Models of ischaemia/re-perfusion
are well established and can be examined. Despite the many
unanswered questions, the great value of this manuscript by
van Laake et al. is that it highlights the necessity of looking
beyond short-term outcomes in interpreting results.
In another prominent study published this year (Laflamme
et al., 2007), HESC-derived CMs treated with a cocktail of
pro-survival factors were injected into rat hearts after
ischemia-reperfusion. Survival of CMs in the graft was
selected for and improved by the cocktail, remuscularising
a significant proportion of myocardium, but similar to the
van Laake et al. study, they did not integrate with host
myocardium. Improvements to cardiac functional para-
meters occurred relative to control treatments, but mea-
surements were taken only at 4 weeks. Thus, the durability
of these effects remain to be determined.
While HESC-derived CMs potentially represent an inex-
haustible supply of human cardiac tissue for use in MRT, the
successful implementation of this approach faces several
hurdles. In addition to the difficulties inherent in any cell-
based therapy (e.g. delivery method, immunological com-
patibility) CMs need to successfully integrate, and the
integration process must also be “measured”, otherwise
cardiac arrhythmias may arise. Further experimentation is
needed to reveal the processes required for CMs engraftment
to the host myocardium and to determine the contribution of
transplanted CMs to long-term improvement of cardiac
muscle performance. Several different stem-cell based
therapies for cardiovascular disease are currently being
evaluated, including the stimulation or injection of
mesenchymal stem cells, bone marrow mononuclear cells,
endothelial progenitor cells and skeletal myoblasts, and the
attempted activation of recently discovered endogenous
cardiac stem cells (Ballard and Edelberg, 2007). Thus, stem-
cell research may provide a number of complementary
therapeutic approaches, including MRT, for cardiovascular
disease. In recent large-scale clinical trials using bone
marrow derived cells (BMDCs) there was an improvement in
cardiac function and a reduction in the hard clinical
endpoints of reoccurrence of infarction and death (reviewed
in Fuster and Sanz, 2006). Despite these encouraging findings
there is no evidence that BMDCs differentiate into cardio-
myocytes or elicit a long-term regenerative response (Fuster
and Sanz, 2006; Schwartz, 2006). Therefore, improved
understanding of both the differentiation process and the
mechanisms underlying the correct integration of trans-
planted cells with the host tissue will help guide MRT in the
clinical setting. Cardiac muscle needs to be fed, and so a
combination of MRT and pro-vascular therapy may be the
next challenge in the much-anticipated transition from
bench to bedside.
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